Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 06 January 2014 | By Alexander Gaffney, RAC,
Pharmaceutical company DaraBiosciences is the latest firm to receive an Untitled Letter from the US Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP), the latest in a long line of recipients alleged to have promoted their products using materials with insufficient risk information.
FDA's Untitled Letter-a stern admonition that nevertheless does not threaten or announce enforcement action for failure to comply with regulation(s)-refers to a promotional piece for DaraBiosciences' Soltamox (tamoxifen citrate), an orally administered breast cancer drug intended for patients whose tumors are estrogen receptor positive.
The drug, like many cancer therapies, is not without serious risks. FDA has assigned the drug a Black Box ("Boxed") Warning for adverse events which include uterine malignancies, stroke and pulmonary embolisms in certain instances. The labeling for the drug also includes a long list of other risks, including patients developing hypercalcemia, endometrial cancer, uterine sarcoma, non-malignant effects on the uterus, liver cancer, non-malignant effects on the liver, fetal harm and others.
The problem, FDA notes in its Untitled Letter to DaraBiosciences, is that you wouldn't know of many of these risks if you had only been exposed to the drug through a cited promotional piece.
The piece is intended to promote the drug's increased palatability over other drugs, with the company touting its liquid, "pleasant tasting" formulation and advantages over pill-based drugs, which can be more difficult to swallow for some patients. This, the piece implies, might increase rates of compliance over alternative FDA-approved therapies.
Unfortunately for the piece, it falls prey to a common error, one cited time and again by OPDP: While the benefits of the drug are listed in some detail in the promotional piece, the risks are not explained in full, and the reader is instructed to see the "full prescribing information" in a piece accompanying the advertising.
While the piece contained some important information, it omitted several important bits of information as well, FDA charged. "By omitting this important risk information, the sales aid misleadingly suggests that Soltamox is safer than has been demonstrated," FDA explained. Even the piece's statement to see the complete prescribing information "does not mitigate the misleading omission of important risk information in the sales aid," FDA added.
The company also failed to include "material facts" relevant to the "full approved indications" for the drug, FDA charged-a relatively uncommon allegation among Untitled Letters, which most often deal with too many statements of efficacy, not too few.
Another common error was called out by OPDP's review staff: While the piece makes implied claims of superiority over other drugs because of the drug's liquid formulation, the company does not back these claims using substantial evidence or clinical experience.
"The totality of these claims and presentations suggests that, as a result of its liquid dosage form, Soltamox offers a therapeutic advantage over other available formulations of tamoxifen, including a positive impact on long-term patient compliance, adherence to treatment, patient preference, convenience, and treatment outcomes," FDA wrote.
Such claims require more substantial evidence than the research cited in the promotional piece, FDA stated. Claims that the drug could improve compliance are, at this time, simply speculation.
FDA requested that the company "immediately cease misbranding Saltamox" and submit a response to FDA by 7 January 2014.
Untitled Letter
Tags: Untitled Letter, substantial evidence
Regulatory Focus newsletters
All the biggest regulatory news and happenings.